Assenagon Asset Management S.A. Decreases Position in Clearside Biomedical, Inc. (NASDAQ:CLSD)

Posted by Defense World Staff on Oct 21st, 2023

Assenagon Asset Management S.A. lessened its holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD – Free Report) by 52.7% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 71,776 shares of the company’s stock after selling 79,862 shares during the period. Assenagon Asset Management S.A. owned approximately 0.12% of Clearside Biomedical worth $80,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Synovus Financial Corp lifted its position in shares of Clearside Biomedical by 166.6% during the 1st quarter. Synovus Financial Corp now owns 74,851 shares of the company’s stock worth $171,000 after purchasing an additional 46,780 shares during the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Clearside Biomedical during the 1st quarter worth $27,000. XTX Topco Ltd lifted its position in shares of Clearside Biomedical by 125.6% during the 1st quarter. XTX Topco Ltd now owns 50,947 shares of the company’s stock worth $117,000 after purchasing an additional 28,366 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Clearside Biomedical by 101.5% during the 1st quarter. Renaissance Technologies LLC now owns 864,951 shares of the company’s stock worth $1,981,000 after purchasing an additional 435,734 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Clearside Biomedical by 5.2% during the 1st quarter. State Street Corp now owns 193,363 shares of the company’s stock worth $443,000 after purchasing an additional 9,475 shares during the last quarter. Hedge funds and other institutional investors own 13.70% of the company’s stock.

Clearside Biomedical Price Performance

Shares of NASDAQ:CLSD opened at $0.82 on Friday. The company’s fifty day moving average price is $0.88 and its 200 day moving average price is $1.06. Clearside Biomedical, Inc. has a 12 month low of $0.75 and a 12 month high of $1.85. The firm has a market capitalization of $50.74 million, a P/E ratio of -1.39 and a beta of 2.13.

Clearside Biomedical (NASDAQ:CLSD – Get Free Report) last posted its quarterly earnings data on Monday, August 14th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). The business had revenue of $1.02 million during the quarter, compared to analyst estimates of $0.21 million. Clearside Biomedical had a negative net margin of 2,217.30% and a negative return on equity of 533.87%. On average, sell-side analysts anticipate that Clearside Biomedical, Inc. will post -0.62 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on CLSD shares. Wedbush reaffirmed an “outperform” rating and set a $5.00 price objective on shares of Clearside Biomedical in a research report on Tuesday, August 15th. StockNews.com started coverage on shares of Clearside Biomedical in a research report on Sunday, October 15th. They set a “sell” rating for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 price objective on shares of Clearside Biomedical in a research report on Tuesday, August 15th. JMP Securities reiterated a “market outperform” rating and set a $5.00 price target on shares of Clearside Biomedical in a research note on Tuesday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Clearside Biomedical in a research note on Tuesday, August 15th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.60.

View Our Latest Research Report on Clearside Biomedical

About Clearside Biomedical

(Free Report)

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.